Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

PF-543 (Citrate)

PF-543 Citrate (Sphingosine Kinase 1 Inhibitor II Citrate) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM. PF-543 Citrate is >100-fold selectivity for SPHK1 over SPHK2. PF-543 Citrate is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC50 of 26.7 nM. PF-543 Citrate induces apoptosis, necrosis, and autophagy[1][2][3].

Product Specifications

CAS Number

[1415562-83-2]

Product Name Alternative

Sphingosine Kinase 1 Inhibitor II (Citrate)

UNSPSC

12352005

Target

Apoptosis; Autophagy; LPL Receptor; SphK

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/PF-543-Citrate.html

Purity

99.47

Solubility

DMSO : 200 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

OC(C(O)=O)(CC(O)=O)CC(O)=O.O=S(C1=CC=CC=C1)(CC2=CC(C)=CC(OCC3=CC=C(CN4[C@@H](CO)CCC4)C=C3)=C2)=O

Molecular Formula

C33H39NO11S

Molecular Weight

657.73

References & Citations

[1]Schnute ME, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012 May 15;444 (1) :79-88.|[2]MacRitchie N, et al. Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. Cell Signal. 2016 Aug;28 (8) :946-55.|[3]Hamada M, et al. Induction of autophagy by sphingosine kinase 1 inhibitor PF-543 in head and neck squamous cell carcinoma cells. Cell Death Discov. 2017 Aug 14;3:17047.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

SphK1

Citation 01

Mol Cell. 2020 Mar 19;77 (6) :1294-1306.e5. |Arch Pharm Res. 2025 Aug;48 (7-8) :798-813.|Cancer Commun (Lond) . 2025 Jul 16.|Cancer Sci. 2020 Jul;111 (7) :2259-2274.|Cell Death Dis. 2024 Aug 1;15 (8) :552.|Curr Res Pharmacol Drug Discov. 2025 Jan 9:8:100212.|Dig Dis Sci. 2025 Jun 5.|Environ Pollut. 2025 Jul 16:383:126846.|Hum Cell. 2020 Jan;33 (1) :57-66.|Inflammation. 2021 Dec;44 (6) :2170-2179.|Pflugers Arch. 2025 Jun;477 (6) :815-826.|Phytomedicine. 2025 Sep 19:148:157271.|Phytother Res. 2025 Aug;39 (8) :3419-3431.|Ren Fail. 2025 Dec;47 (1) :2568972.|Sci China Life Sci. 2022 Feb;65 (2) :341-361.|Sci Rep. 2020 Aug 14;10 (1) :13834.|FASEB J. 2024 Jan 31;38 (2) :e23417.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

AMP Activated Protein Kinase alpha1 (AMPK a1) (APC)
A1475-01-APC 100 µL

AMP Activated Protein Kinase alpha1 (AMPK a1) (APC)

Ask
View Details
Mouse Mouse IgG Fc Isotype Control
NBP1-96784 1 mg

Mouse Mouse IgG Fc Isotype Control

Ask
View Details
Human SYT15 (NM_181519) AAV Particle
RC222405A1V 250 µL

Human SYT15 (NM_181519) AAV Particle

Ask
View Details
Mouse Monoclonal FoxC2 Antibody (2H3)
H00002303-M02 0.1 mg

Mouse Monoclonal FoxC2 Antibody (2H3)

Ask
View Details
PTCD3 CRISPR All-in-one AAV vector set (with saCas9)(Human)
38061151 3x 1.0 µg DNA

PTCD3 CRISPR All-in-one AAV vector set (with saCas9)(Human)

Ask
View Details
LA Control Plasma Weak
SC082K 6x 1 mL

LA Control Plasma Weak

Ask
View Details